<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE collection SYSTEM "BioC.dtd">
<collection><source>GO_Annotation</source><date>20130316</date><key>go_annotation.key</key><document><id>19473976</id><passage><infon key="type">paragraph</infon><offset>9751</offset><annotation id="19473976_1"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IPI</infon><infon key="type">GOA</infon><location offset="10301" length="123"/><text>At this point the medium was replaced and DIDS-mediated cross-linking of MCT1 to embigin carried out after a further 24 h.</text></annotation><annotation id="19473976_2"><infon key="gene">Emp(81505)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IPI</infon><infon key="type">GOA</infon><location offset="10301" length="123"/><text>At this point the medium was replaced and DIDS-mediated cross-linking of MCT1 to embigin carried out after a further 24 h.</text></annotation></passage><passage><infon key="type">paragraph</infon><offset>13810</offset><annotation id="19473976_3"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">lactate transmembrane transport|GO:0035873</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="13810" length="118"/><text>Fig. 1 shows that the mutation of Lys38 to arginine totally abolished lactate transport by MCT1 expressed in oocytes. </text></annotation><annotation id="19473976_4"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">lactate transmembrane transport|GO:0035873</infon><infon key="goevidence">IDA</infon><infon key="type">GOA</infon><location offset="13810" length="118"/><text>Fig. 1 shows that the mutation of Lys38 to arginine totally abolished lactate transport by MCT1 expressed in oocytes. </text></annotation><annotation id="19473976_5"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">plasma membrane|GO:0005886</infon><infon key="goevidence">IDA</infon><infon key="type">GOA</infon><location offset="14058" length="80"/><text>Neither of these mutations prevented expression of MCT1 at the plasma membrane. </text></annotation><annotation id="19473976_6"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">cellular response to organic cyclic compound|GO:0071407</infon><infon key="goevidence">IEP</infon><infon key="type">GOA</infon><location offset="14282" length="88"/><text>2 mm DIDS caused ~60% reversible and irreversible inhibition of wild type MCT1 activity.</text></annotation></passage><passage><infon key="type">fig_caption</infon><offset>14739</offset><annotation id="19473976_7"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">lactate transmembrane transport|GO:0035873</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="15448" length="237"/><text>and sections of oocytes subject to immunofluorescence microscopy to confirm that the lack of lactate transport by the K38Q (inset B) or K38R (inset C) mutants is not due to reduced MCT1 expression compared with wild type MCT1 (inset A). </text></annotation></passage><passage><infon key="type">fig_caption</infon><offset>16925</offset><annotation id="19473976_8"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">lactate transmembrane transport|GO:0035873</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="17493" length="114"/><text>All of these mutant forms of MCT1 were active and supported rates of lactate transport within 45-120% of wild type</text></annotation><annotation id="19473976_9"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">lactate transmembrane transport|GO:0035873</infon><infon key="goevidence">IDA</infon><infon key="type">GOA</infon><location offset="17493" length="114"/><text>All of these mutant forms of MCT1 were active and supported rates of lactate transport within 45-120% of wild type</text></annotation><annotation id="19473976_10"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">cellular response to organic cyclic compound|GO:0071407</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="17656" length="230"/><text>Mutations showing a significant reduction in reversible and irreversible inhibition (p &lt; 0.05 by Student's t test) are indicated with a star, whereas those in which irreversible inhibition is abolished are indicated with an arrow.</text></annotation><annotation id="19473976_11"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">cellular response to organic cyclic compound|GO:0071407</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="17656" length="230"/><text>Mutations showing a significant reduction in reversible and irreversible inhibition (p &lt; 0.05 by Student's t test) are indicated with a star, whereas those in which irreversible inhibition is abolished are indicated with an arrow.</text></annotation></passage><passage><infon key="type">paragraph</infon><offset>17973</offset><annotation id="19473976_12"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">cellular response to organic cyclic compound|GO:0071407</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="19302" length="198"/><text>However, replacement of these three lysine residues with glutamines caused a reduction in reversible inhibition while abolishing irreversible inhibition as predicted from the double mutants of Fig. </text></annotation></passage><passage><infon key="type">paragraph</infon><offset>23235</offset><annotation id="19473976_13"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="23235" length="154"/><text>In Fig. 3A we show that mutation of Lys38, Lys45, or Lys282 to glutamine gave a considerable reduction in DIDS-mediated cross-linking of MCT1 to embigin, </text></annotation><annotation id="19473976_14"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="23572" length="98"/><text>but the K38Q/K45Q, K38Q/K282Q and K45Q/282Q double mutants almost totally abolished cross-linking </text></annotation><annotation id="19473976_15"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="24257" length="100"/><text>Only with the hextuple mutant K38R/K45R/K282R/K284R/K290R/K413R was cross-linking totally prevented.</text></annotation><annotation id="19473976_16"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="24842" length="174"/><text>Thus the K38R/K45R/K282R/284R/K413R mutant still shows significant, although reduced, cross-linking, whereas the K38R/K45R/K282R/K284R/K290R/K413R mutant does not (Fig. 3C). </text></annotation><annotation id="19473976_17"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IPI</infon><infon key="type">GOA</infon><location offset="23572" length="98"/><text>but the K38Q/K45Q, K38Q/K282Q and K45Q/282Q double mutants almost totally abolished cross-linking </text></annotation><annotation id="19473976_18"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IPI</infon><infon key="type">GOA</infon><location offset="24257" length="100"/><text>Only with the hextuple mutant K38R/K45R/K282R/K284R/K290R/K413R was cross-linking totally prevented.</text></annotation></passage><passage><infon key="type">paragraph</infon><offset>29216</offset><annotation id="19473976_19"><infon key="gene">Emb(114511)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="30420" length="232"/><text>However, when we mutated either Lys160 or Lys164 to glutamine DIDS-mediated cross-linking was reduced with the greatest effect observed with K164Q, whereas the K160Q/K164Q double mutant showed no detectable cross-linking (Fig. 6B). </text></annotation></passage><passage><infon key="type">fig_caption</infon><offset>31102</offset><annotation id="19473976_20"><infon key="gene">Emb(114511)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="31102" length="91"/><text>Lysine residues 160 and 164 of embigin are involved in DIDS-mediated cross-linking to MCT1.</text></annotation></passage><passage><infon key="type">paragraph</infon><offset>31883</offset><annotation id="19473976_21"><infon key="gene">Emb(114511)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="31883" length="182"/><text>The data of Fig. 6B also demonstrate that we were able to abolish DIDS-mediated cross-linking of MCT1 to embigin by mutating cysteines at position 180 and 182 of embigin to alanine. </text></annotation></passage><passage><infon key="type">paragraph</infon><offset>32642</offset><annotation id="19473976_22"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">cellular response to organic cyclic compound|GO:0071407</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="33307" length="88"/><text>Mutation of Lys282 but not Lys45 or Lys413 to glutamine reduces both types of inhibition</text></annotation><annotation id="19473976_23"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">cellular response to organic cyclic compound|GO:0071407</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="33460" length="200"/><text>This is confirmed by the observation that both the K45Q/K282Q and K282Q/K413Q mutants show no irreversible inhibition, whereas the K45Q/K413Q mutant retains reduced irreversible inhibition (Fig. 2B). </text></annotation></passage><passage><infon key="type">paragraph</infon><offset>43722</offset><annotation id="19473976_24"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">cellular response to organic cyclic compound|GO:0071407</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="44534" length="242"/><text>An unexpected experimental finding was that both the K45Q/K282Q/K284Q and K282Q/K284Q/K413Q triple mutants showed some irreversible inhibition by DIDS (Fig. 3C), whereas neither the K45Q/K282Q nor the K282Q/K413Q double mutant did (Fig. 3B). </text></annotation><annotation id="19473976_25"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">lactate transmembrane transport|GO:0035873</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="44534" length="242"/><text>An unexpected experimental finding was that both the K45Q/K282Q/K284Q and K282Q/K284Q/K413Q triple mutants showed some irreversible inhibition by DIDS (Fig. 3C), whereas neither the K45Q/K282Q nor the K282Q/K413Q double mutant did (Fig. 3B). </text></annotation></passage><passage><infon key="type">paragraph</infon><offset>46513</offset><annotation id="19473976_26"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="46828" length="69"/><text>However, cross-linking is not totally abolished in the K38Q mutants, </text></annotation><annotation id="19473976_27"><infon key="gene">Slc16a1(25027)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="46982" length="291"/><text>Lys290 appears to be the residue that is covalently modified by the isothiocyanate group of DIDS under these conditions because mutation of lysine residues 38, 45, 282, 284, and 413 to arginines maintained some cross-linking, but this was prevented when Lys290 was also mutated to arginine. </text></annotation></passage><passage><infon key="type">paragraph</infon><offset>47539</offset><annotation id="19473976_28"><infon key="gene">Emb(114511)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="47608" length="249"/><text>we employed lysine and cysteine mutants of embigin (Fig. 6). These data implicate Lys160 and Lys164 in the cross-linking and suggest that the Ig-like V domain of embigin nearest to the membrane may bend over toward the extracellular surface of MCT1.</text></annotation><annotation id="19473976_29"><infon key="gene">Emb(114511)</infon><infon key="go-term">organic cyclic compound binding|GO:0097159</infon><infon key="goevidence">IMP</infon><infon key="type">GOA</infon><location offset="48113" length="151"/><text>Furthermore, we found that C180A/C182A embigin also failed to cross-link with MCT1 consistent with disruption of the disulfide bridge in the V domain, </text></annotation></passage></document></collection>
